Walder Wyss advised UBS Switzerland, which served as the mandated lead arranger and underwriter, financing Polygena’s acquisition of Kubo Tech and its subsidiaries. The companies involved Polygena is a Swiss industrial group part of the Helvetica Capital and Wistama portfolio. Kubo Tech specialises in high-quality seals, springs, and molded rubber components. The transaction was successfully […]
Homburger acted as legal advisor to UBS Switzerland in its role as mandated lead arranger, sole underwriter, bookrunner, agent, security agent, and original lender for the financing of United Grinding Group’s acquisition of GF
Advestra has acted as Swiss legal counsel to the initial purchasers and lenders in connection with the financing of Bain Capital’s acquisition of SO.MA.CI.S. and the subsequent acquisition of AT&
BGPartner has advised OrbiMed and Novo Holdings on Swiss legal matters related to the USD 200 million Series A financing of Windward Bio Group, a Swiss-based clinical-stage drug development company, advised by Homburger. The financing round
Baker McKenzie Switzerland advised R&S Group, a manufacturer of electrical infrastructure, in connection with its new CHF 160 million term loan (TL) and CHF 30 million revolving credit facilities (RCF) agreement with UBS Switzerland, advised
Walder Wyss advised Anybotics, an AI-driven robotic inspection solutions company, on raising an additional USD 60 million on its latest financing round led by Qualcomm Ventures and Supernova Invest, advised by Lenz & Staehelin. In total,
Niederer Kraft Frey (NKF) advised Bain Capital and its affiliate Castello Bidco on the Swiss law aspects of Castello’s debut senior secured floating rate notes issuance of EUR 550 million due 2031, and its entry into
Advestra advised Zürcher Kantonalbank as agent, security agent and lender and the other syndicate banks as lenders on the CHF 155 million syndicated cred
Niederer Kraft Frey advised Luzerner Kantonalbank, acting as agent, and the syndicate of banks on all aspects regarding the amendment of the existing financing for Hochdorf Swiss Nutrition (HSN), in the context of AS Equity
Homburger advised Noema Pharma, a clinical-stage biotech company, on its successful closing of a Series B extension financing round with an investment from EQT Life Sciences, and with continued support from Jeito and Forbion, all
